C. Watkins

S. Thongprasert, C. Watkins, R. Perng, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

V. Valero, C. Watkins, M. Cristofanilli, 2010, Clinical Cancer Research.

Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes

S. Paganoni, S. Hendrix, M. Cudkowicz, 2022, Muscle & nerve.

Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.

C. Watkins, P. Nathan, Kevin B. Kim, 2022, Journal of Clinical Oncology.

Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM).

J. Kirkwood, C. Watkins, L. Demidov, 2022, Journal of Clinical Oncology.

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.

C. Watkins, J. Morrell, D. Kallend, 2005, International journal of cardiology.

Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.

C. Watkins, D. Gandara, R. Rosenthal, 2019, Clinical lung cancer.

Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis

T. Strandberg, C. Watkins, F. Fonseca, 2006, Current medical research and opinion.

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.

P. Barter, C. Watkins, J. Bonnet, 2004, American heart journal.

A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time‐to‐event data

C. Watkins, I. Bennett, 2018, Research synthesis methods.

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

Collaborative platform to facilitate engineering decision-making

Stephanie Glendinning, Richard Dawson, Mike Martin, 2013 .

1P-0281 Switching to rosuvastatin from other statins has beneficial effects on lipid ratios

C. Watkins, J. Bonnet, H. Schuster, 2003 .

A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

V. Valero, C. Watkins, M. Cristofanilli, 2008 .

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

T. Mok, Yi-long Wu, S. Thongprasert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

H. Wildiers, J. Carmichael, C. Watkins, 2013, Breast Cancer Research.

Utility values in health technology assessments: a statistician's perspective

C. Watkins, H. Mann, C. Fletcher, 2014, Pharmaceutical statistics.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

C. Watkins, P. Bunn, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fractional Polynomial Modelling In Network Meta-Analyses Of Cancer Immunotherapies In Advanced Non-Small Cell Lung Cancer (NSCLC)

C. Watkins, P. Chu, 2017 .

Decision‐making in early clinical drug development

James Matcham, Pat Mitchell, Paul Frewer, 2016, Pharmaceutical statistics.